Collegium Pharmaceutical, Inc
A pharmaceutical company making medicines for pain and ADHD, including the opioid painkiller Xtampza ER (built on its DETERx abuse-deterrent technology), Belbuca, the Nucynta products, and Jornay PM, an evening-dosed ADHD stimulant. Founded in 2002 by Michael Heffernan to develop safer opioids, its name comes from the Latin "collegium," meaning a band of colleagues working together. The company even named its technology DETERx — a nod to deterring misuse, which is why its microsphere-in-capsule pain pills are hard to crush or inject.
Sold 25.0K
Bought 200.0K · Sold 1.00M
Bought 150.0K
Bought 100.0K
Bought 150.0K
Bought 150.0K
Granted 1.57M · Sold 760.2K
Granted 166.6K · Bought 10.0K · Sold 10.0K
Granted 94.7K · Bought 150.0K · Sold 22.4K
Granted 217.8K
Granted 365.7K · Sold 108.2K
Granted 259.6K · Sold 92.2K
Granted 144.9K
Granted 94.7K · Sold 5.4K
Granted 507.1K · Sold 283.2K
Granted 97.1K · Bought 2.4K · Sold 34.9K
Granted 142.7K · Sold 28.1K
Granted 99.6K · Sold 20.2K
Granted 556.1K · Sold 349.2K
Granted 108.7K · Sold 37.7K
Granted 65.0K · Sold 3.6K
Granted 52.5K
Granted 798.0K · Sold 1.22M
Granted 49.4K
Granted 28.3K
Granted 31.3K · Sold 4.5K
Granted 30.9K · Bought 200.0K · Sold 1.05M
Granted 20.5K
Granted 17.5K
Granted 11.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rosen David Efraim +1 co-filer10% owner · 1 transaction | — | 6.29Mas of Aug 2025 | — | — | 25.0K |
| Enright Patrick G +4 co-filers10% owner · 6 transactions | — | 2.32Mas of Dec 2017 | — | 200.0K | 1.00M |
| Kaneko Yasunori10% owner · 2 transactions | — | 2.15Mas of Dec 2017 | — | — | — |
| Skyline Venture Partners V LP +1 co-filer10% owner · 1 transaction | — | 2.15Mas of Dec 2017 | — | — | — |
| Kaneko Yasunori +2 co-filers10% owner · 4 transactions | — | 1.94Mas of May 2015 | — | 150.0K | — |
| Bonderman David +2 co-filersFormer 10% Owner · 2 transactions | — | 1.23Mas of May 2015 | — | 100.0K | — |
| Every Nathan R +6 co-filers10% owner · 5 transactions | — | 582.5Kas of May 2015 | — | 150.0K | — |
| Heron Patrick JDirector, 10% owner · 5 transactions | — | 582.5Kas of May 2015 | — | 150.0K | — |
| Ciaffoni JosephPresident and CEO, Director · 94 transactions | — | 526.3Kas of Feb 2024 | 1.57M | — | 760.2K |
| Brannelly PaulExecutive Vice President & CFO · 37 transactions | — | 221.4Kas of Feb 2021 | 166.6K | 10.0K | 10.0K |
| Freund John GordonDirector · 29 transactions | — | 195.0K | 94.7K | 150.0K | 22.4K |
| Karnani VikramPresident and CEO, Director · 5 transactions | — | 176.6K | 217.8K | — | — |
| Tupper ColleenEVP & Chief Financial Officer · 32 transactions | — | 147.3K | 365.7K | — | 108.2K |
| Fleming Alison BEVP & Chief Technical Officer · 63 transactions | — | 143.7Kas of Aug 2021 | 259.6K | — | 92.2K |
| Malamut RichardEVP and Chief Medical Officer · 12 transactions | — | 130.3Kas of Feb 2022 | 144.9K | — | — |
| Santini GinoDirector · 12 transactions | — | 112.5K | 94.7K | — | 5.4K |
| Kuhlmann Shirley R.EVP and General Counsel · 53 transactions | — | 108.1Kas of Mar 2025 | 507.1K | — | 283.2K |
| Fallon John A.Director · 12 transactions | — | 99.5K | 97.1K | 2.4K | 34.9K |
| Smith Thomas BEVP and Chief Medical Officer · 16 transactions | — | 85.3K | 142.7K | — | 28.1K |
| Dieter DavidEVP & General Counsel · 7 transactions | — | 77.1K | 99.6K | — | 20.2K |
| Dreyer ScottEVP & Chief Commercial Officer · 72 transactions | — | 75.3K | 556.1K | — | 349.2K |
| Bohlin Garen GDirector · 13 transactions | — | 71.0K | 108.7K | — | 37.7K |
| Balice-Gordon Rita J.Director · 8 transactions | — | 61.4K | 65.0K | — | 3.6K |
| Melincoff Gwen ADirector · 7 transactions | — | 52.5Kas of May 2024 | 52.5K | — | — |
| Heffernan Michael ThomasDirector · 87 transactions | — | 50.3Kas of Feb 2025 | 798.0K | — | 1.22M |
| McFarlane Neil F.Director · 4 transactions | — | 49.4Kas of May 2024 | 49.4K | — | — |
| Paya Carlos VDirector · 2 transactions | — | 28.3K | 28.3K | — | — |
| Lurker NancyDirector · 4 transactions | — | 26.8K | 31.3K | — | 4.5K |
| Hirsch DavidDirector · 16 transactions | — | 21.2Kas of May 2020 | 30.9K | 200.0K | 1.05M |
| Duke Barry SSee remarks · 5 transactions | — | 20.1Kas of Mar 2017 | 20.5K | — | — |
| Glancy Donovan MichaelDirector · 1 transaction | — | 17.5K | 17.5K | — | — |
| Schroeder Theodore RDirector · 3 transactions | — | 11.0Kas of May 2020 | 11.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.94M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.